IGI

Western Asset Term Funds Announce Stockholder Proposals

Retrieved on: 
Tuesday, February 20, 2024

Western Asset Investment Grade Defined Opportunity Trust Inc. (NYSE: IGI) and Western Asset Global Corporate Defined Opportunity Fund Inc. (NYSE: GDO) (individually, a “Fund” and collectively, the “Funds”) announced today approval by each Fund’s Board of Directors of a proposal that will allow stockholders of each Fund to remain invested, subject to stockholder approval.

Key Points: 
  • Western Asset Investment Grade Defined Opportunity Trust Inc. (NYSE: IGI) and Western Asset Global Corporate Defined Opportunity Fund Inc. (NYSE: GDO) (individually, a “Fund” and collectively, the “Funds”) announced today approval by each Fund’s Board of Directors of a proposal that will allow stockholders of each Fund to remain invested, subject to stockholder approval.
  • If a Fund’s net assets following the tender offer are expected to be $50 million or greater, the tender offer will be completed and such Fund’s term will be eliminated.
  • If a Fund’s term is eliminated, the Fund’s name will change to reflect the elimination to “Western Asset Investment Grade Opportunity Trust Inc.” and “Western Asset Global Corporate Opportunity Fund Inc.” for IGI and GDO, respectively.
  • The approval of each Fund’s Amendment Proposal is not contingent upon the approval of the other Fund’s Amendment Proposal.

Ichnos and Glenmark take a collaborative leap to accelerate innovation in Cancer Treatment with their alliance - 'Ichnos Glenmark Innovation'

Retrieved on: 
Tuesday, January 30, 2024

This alliance brings together drug innovation capabilities of Ichnos and Glenmark to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors.

Key Points: 
  • This alliance brings together drug innovation capabilities of Ichnos and Glenmark to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors.
  • NEW YORK, Jan. 30, 2024 /PRNewswire/ -- Ichnos Sciences Inc. (Ichnos), a global, fully integrated, clinical-stage biotech company and Glenmark Pharmaceuticals Ltd. (Glenmark), a leading, research-driven, global pharmaceutical company, today announced the launch of their alliance – Ichnos Glenmark Innovation – to accelerate new drug discovery in cancer treatment.
  • "We are proud to announce the Ichnos Glenmark Innovation alliance, which brings together the legacy of Glenmark and passion of Ichnos to accelerate the search for curing cancer.
  • remarked Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals Ltd.
    Cyril Konto, President and CEO, Ichnos Glenmark Innovation, said, "Ichnos Glenmark Innovation is a collaborative venture backed by a strong, collective pipeline of novel multispecifics and small molecules.

IGI to Release Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024

Retrieved on: 
Tuesday, January 23, 2024

International General Insurance Holdings Ltd. (“IGI” or the “Company”) (NASDAQ: IGIC) today announced that it expects to release financial results for the fourth quarter and full year 2023, on Tuesday, March 12, 2024, after the close of the U.S. financial markets.

Key Points: 
  • International General Insurance Holdings Ltd. (“IGI” or the “Company”) (NASDAQ: IGIC) today announced that it expects to release financial results for the fourth quarter and full year 2023, on Tuesday, March 12, 2024, after the close of the U.S. financial markets.
  • The results, along with an accompanying slide presentation, will be posted in the Investors section of the Company website at www.iginsure.com .
  • The Company will host an investor teleconference, including a question and answer period, on Wednesday, March 13, 2024, at 9:00 a.m. Eastern time to discuss the fourth quarter and full year 2023 financial results.
  • A live, listen-only webcast of the call will be available via the Investors section of the Company website at www.iginsure.com , and the webcast will be archived in the Investors section of the Company website.

Danaher, Jennifer Doudna, and Innovative Genomics Institute Launch Danaher-IGI Beacon for CRISPR Cures with Aim to Address Hundreds of Diseases Using Gene-editing Platform Solution

Retrieved on: 
Tuesday, January 9, 2024

The center, known as the Danaher-IGI Beacon for CRISPR Cures, aims to use CRISPR-based gene editing to permanently address hundreds of diseases with a unified research, development and regulatory approach.

Key Points: 
  • The center, known as the Danaher-IGI Beacon for CRISPR Cures, aims to use CRISPR-based gene editing to permanently address hundreds of diseases with a unified research, development and regulatory approach.
  • The collaboration, which enables a substantial new research program at IGI, is the largest Danaher Beacon to date.
  • The Beacons program funds pioneering academic research with the goal of developing innovative technologies and applications for human health.
  • The unique nature of CRISPR makes it ideal for developing and deploying a platform capability for CRISPR cures on demand.

UpHealth Provides Corporate Update And Issues Financial Results For The Third Quarter Of 2023

Retrieved on: 
Monday, November 20, 2023

DELRAY BEACH, Fla., Nov. 20, 2023 (GLOBE NEWSWIRE) -- UpHealth, Inc. (“we,” “UpHealth,” or the “Company”) (NYSE: UPH), today issued a corporate update in the form of a letter to shareholders on behalf of CEO, Martin Beck, inclusive of financial results for the third quarter ended September 30, 2023.

Key Points: 
  • For the third quarter of 2023, we reported total revenues of $32.7 million, compared to $38.7 million in the third quarter of 2022.
  • Our gross margin expanded to 54% in the third quarter of 2023, up from 44% in the third quarter of 2022.
  • Due to the deconsolidation of UpHealth Holdings, this excludes approximately $35.6 million of cash at UpHealth Holdings as of September 30, 2023.
  • On September 19, 2023, UpHealth Holdings, a subsidiary of UpHealth, filed a voluntary petition under Chapter 11 of the U.S. Bankruptcy Code.

Icahn School of Medicine at Mount Sinai Secures $5 Million NIH Grant for Cutting-Edge Cancer Target Discovery and Development Center

Retrieved on: 
Wednesday, November 15, 2023

NEW YORK, Nov. 15, 2023 /PRNewswire-PRWeb/ -- The Department of Immunology and Immunotherapy and the Icahn Genomics Institute (IGI) at the Icahn School of Medicine at Mount Sinai have been awarded a $5 million grant from the National Cancer Institute (NCI) of the National Institutes of Health to establish a state-of-the-art center dedicated to the discovery and development of cutting-edge targets for cancer therapy.

Key Points: 
  • The new Cancer Target Discovery and Development Center aims to find better ways to fight cancer and advance the field, bringing hope to patients and their families.
  • The new Cancer Target Discovery and Development Center aims to find better ways to fight cancer and advance the field, bringing hope to patients and their families.
  • "Cancer target discovery research has traditionally concentrated on pinpointing genes that facilitate cancer cell growth and survival.
  • It allows them to see how cancer genes affect not only cancer cells but also the immune system within tumors.

AM Best Affirms Credit Ratings of International General Insurance Holdings Ltd. and Its Subsidiaries

Retrieved on: 
Wednesday, November 8, 2023

AM Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of “a” (Excellent) of International General Insurance Co. Ltd., (IGICL) (Bermuda), International General Insurance Company (UK) Limited (IGIUK) (United Kingdom) and International General Insurance Company (Europe) P.L.C.

Key Points: 
  • AM Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of “a” (Excellent) of International General Insurance Co. Ltd., (IGICL) (Bermuda), International General Insurance Company (UK) Limited (IGIUK) (United Kingdom) and International General Insurance Company (Europe) P.L.C.
  • Concurrently, AM Best has affirmed the Long-Term ICR of “bbb” (Good) of International General Insurance Holdings Ltd. (IGI) (Bermuda) [NASDAQ: IGIC].
  • For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best’s Credit Ratings .
  • For information on the proper use of Best’s Credit Ratings, Best’s Performance Assessments, Best’s Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best’s Ratings & Assessments .

Adamas One Corp Announces Initial Delivery of Lab-Grown Colorless Diamonds

Retrieved on: 
Thursday, November 2, 2023

SCOTTSDALE, Ariz., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Adamas One Corp. (Nasdaq: JEWL) (“Adamas One,” “Adamas” or the “Company”), The Original Lab-Grown Diamond Company™, a high-tech company that leverages proprietary technology to produce high-quality, single-crystal, Lab-Grown Diamonds for jewelry and diamond materials for industrial uses, announces the initial delivery of colorless diamonds.

Key Points: 
  • SCOTTSDALE, Ariz., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Adamas One Corp. (Nasdaq: JEWL) (“Adamas One,” “Adamas” or the “Company”), The Original Lab-Grown Diamond Company™, a high-tech company that leverages proprietary technology to produce high-quality, single-crystal, Lab-Grown Diamonds for jewelry and diamond materials for industrial uses, announces the initial delivery of colorless diamonds.
  • Adamas One’s extensive internal R&D efforts lead to the successful creation of D, E and F diamonds, which are considered to be colorless as determined by gem grading labs such as GIA, IGI, and EGL.
  • “This successful delivery of high-quality lab-grown colorless diamonds is due to our consistent drive to advance our diamond product offerings.
  • Current industry reports are showing lab-grown diamonds now represent more than 50% of diamond sales in the US,” concluded Mr. Grdina.

IGI to Release Third Quarter and Nine Months 2023 Financial Results on November 14, 2023

Retrieved on: 
Tuesday, October 17, 2023

---

Key Points: 
  • International General Insurance Holdings Ltd. (“IGI” or the “Company”) (NASDAQ: IGIC) today announced that it expects to release financial results for the third quarter and first nine months of 2023, on Tuesday, November 14, 2023, after the close of the U.S. financial markets.
  • The results, along with an accompanying slide presentation, will be posted in the Investors section of the Company website at www.iginsure.com .
  • The Company will host an investor teleconference, including a question and answer period, on Wednesday, November 15, 2023, at 9:00 a.m. Eastern time to discuss the third quarter and nine months 2023 financial results.
  • A live, listen-only webcast of the call will be available via the Investors section of the Company website at www.iginsure.com , and the webcast will be archived in the Investors section of the Company website.

Regel Therapeutics Awarded $1 Million from HS Chau Women in Enterprising Science Program at the Innovative Genomics Institute to Continue Developing Its Gene Modulation Technology

Retrieved on: 
Friday, September 29, 2023

The HS Chau WIES Program at the IGI is committed to addressing gender inequity in biotechnology and supporting entrepreneurs to develop innovative solutions for some of the world's greatest health problems.

Key Points: 
  • The HS Chau WIES Program at the IGI is committed to addressing gender inequity in biotechnology and supporting entrepreneurs to develop innovative solutions for some of the world's greatest health problems.
  • The IGI is working to advance revolutionary biotechnology that translates scientific breakthroughs into real-world solutions that are accessible and affordable.
  • With the generous philanthropic support of Solina Chau Hoi Shuen of Horizons Ventures, the IGI launched the WIES program to support and guide entrepreneurs who align with its mission.
  • Scientists selected for the program receive access to world-class resources to further their research using technologies such as CRISPR.